AstraZeneca
AstraZeneca/ News/ News/ R&D
Breakthrough designation AstraZeneca’s severe asthma drug
Piotr Wnuk
Amgen, AstraZeneca, severe asthma, tezepelumab
0 Comment
AstraZeneca/ Diabetes/ Diabetes/ News/ News/ R&D/ UK & Europe
AstraZeneca improves diabetes pen to maintain its market share
AstraZeneca/ News/ News/ R&D
AstraZeneca to present the latest cardiovascular research
Piotr Wnuk
AstraZeneca, cardiovascular, hyperkalaemia, MedImmune
0 Comment
AstraZeneca/ News/ Pfizer/ Roche
Drug firms fight US government’s Iraq corruption probe
Joy Persaud
litigation
0 Comment
US Department of Justice investigating J&J, Pfizer, Roche and others
AstraZeneca/ Merck Inc/ News/ News/ News/ Oncology/ R&D/ Rare diseases/ Top stories/ UK & Europe
Neurofibromatosis treatment granted orphan status by EMA
Piotr Wnuk
ASCO 2018, AstraZeneca, ema, genetic, Merck & Co, Neurofibromatosis, NF1, Oncology, Selumetinib
0 Comment
AstraZeneca/ Market Access/ News/ News/ Top stories
AZ suffers setback as NICE slaps restrictions on Fasenra
Richard Staines
AstraZeneca, market access, respiratory
0 Comment
Fasenra can only be used after GSK rival, NICE says in draft decision
AstraZeneca/ News/ News/ R&D/ Top pharmaceutical companies
AZ forges surprise R&D deal with virus gene therapy biotech
Piotr Wnuk
AstraZeneca, gene therapy, genetics, MedImmune
0 Comment